Sosei Group ( (JP:4565) ) just unveiled an announcement.
Nxera Pharma announced a correction to its previous notice regarding the reduction of capital reserve and disposition of surplus. The correction involves changes in the amounts transferred to retained earnings, which will be used to compensate for the company’s deficit. This adjustment reflects the company’s efforts to manage its financial structure effectively, potentially impacting its financial stability and stakeholder interests.
More about Sosei Group
Nxera Pharma is a technology-driven biopharmaceutical company focused on developing specialty medicines to address unmet medical needs in Japan and globally. The company is advancing a pipeline of over 30 active programs targeting neurology, gastrointestinal and immunology, metabolic disorders, and rare diseases using its unique GPCR-targeted drug discovery platform, NxWaveTM. Nxera employs over 350 people across key locations worldwide and is listed on the Tokyo Stock Exchange.
YTD Price Performance: -1.21%
Average Trading Volume: 614
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $506M
Learn more about 4565 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com